Takeda Pharmaceutical announced the cancellation of the registration of new share issuance related to the LTIP (Long-Term Incentive Plan) and the decision to register a new issuance. The maximum planned amount is 240 billion yen, with the fund usage limited to LTIP, and dilutive impact estimated at approximately 1.1%.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4502","jir_company_name":"Takeda Pharmaceutical Company Limited","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-06-01","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4502-20260601-01.pdf","jir_short_summary":"Takeda Pharmaceutical announced the cancellation of the registration of new share issuance related to the LTIP (Long-Term Incentive Plan) and the decision to register a new issuance. The maximum planned amount is 240 billion yen, with the fund usage limited to LTIP, and dilutive impact estimated at approximately 1.1%.","jir_summary":"### Overview of Capital Policy\nTakeda Pharmaceutical decided to cancel the registration of the share issuance submitted in June 2025 and to register a new issuance in relation to the implementation of the LTIP (Long-Term Incentive Plan). The purpose of this new registration is to enable flexible share issuances and disposal of treasury stock. The maximum planned amount is estimated at 240 billion yen. It is not aimed at fundraising, but limited to stock grants based on the LTIP, with a projected dilutive impact of about 1.1%. The issuance period is from June 9, 2026, to June 8, 2027.\n\n### Impact on Shareholders and Future Outlook\nThis capital policy aims to continue the LTIP and strengthen employee incentives. Since it does not involve fundraising, the direct impact on shareholders' ownership ratios is limited. The upper limit of the planned issuance amount is 240 billion yen, with an estimated dilutive rate of about 1.1%. Going forward, Takeda Pharmaceutical will continue to promote flexible capital policy with the goal of enhancing long-term corporate value through employee incentive schemes.","jir_financial_highlights":"Planned Issuance Amount: 240,000 million yen (Unknown)\nDilution Rate: Approximately 1.1% (Unknown)\nIssuance Period: June 9, 2026 \u2013 June 8, 2027 (Unknown)","jir_category":"","jir_hashtags":"#TakedaPharmaceutical, #CapitalPolicy, #JapanStocks","jir_key_figures":"Planned issuance amount: 240,000 million yen (max)\nDilution rate: Approximately 1.1%\nIssuance period: June 9, 2026 \u2013 June 8, 2027","jir_meta_title":"\u3010Takeda Pharmaceutical\u3011Review of Share Issuance Registration Related to LTIP\uff5cJune 2026","jir_meta_description":"Takeda Pharmaceutical announced the cancellation of existing share issuance registration and the registration of a new issuance related to LTIP. The planned issuance amount is up to 240 billion yen, with a dilutive impact of about 1.1%.","jir_og_title":"\u3010Takeda Pharmaceutical\u3011Review of Capital Policy Related to LTIP\uff5cJune 2026","jir_og_description":"Takeda Pharmaceutical is reviewing the registration of new share issuance related to LTIP, with maximum planned issuance of 240 billion yen. Dilution is about 1.1%, aiming to strengthen long-term incentives.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6852,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-56183","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n